Neoplasms Clinical Trial
Official title:
A Feasibility Study in Acupuncture for Symptom Management in Palliative Care.
Research question: Can acupuncture improve symptom control and quality of life (QOL) in
patients with advanced incurable cancer?
The purposes of this study is to investigate the feasibility of performing a randomized
trial with acupuncture in improving symptom control and quality of life (QOL) in patients
with advanced incurable cancer at the BC Cancer Agency, Vancouver Island Centre in Victoria.
We will:
- Evaluate whether subjects who are receiving palliative care for cancer related symptoms
can tolerate and complete to a course of acupuncture treatments.
- Evaluate whether it is possible to conduct a study using acupuncture on cancer
patients.
Patients with advanced cancer suffer from many symptoms which dramatically reduce their
Quality of Life (QOL). There have been significant improvements in the management of pain,
nausea and constipation, but other common symptoms such as fatigue, anxiety, depression, and
a lack of well-being are not readily addressed by conventional therapies. As cancer patients
usually present with numerous symptoms, it would be important to try to address all of these
globally, instead of only treating individual symptoms that respond well to conventional
therapy. Attempts at controlling individual symptoms can also give rise to iatrogenic
effects. One well known example is constipation occurring in patients who are on opiate
analgesics. Successful treatment from the caregiver's perspective is often scored against
each individual symptom that is being treated. From the patient's point of view, it is the
interplay of the whole treatment package that succeeds or fails in improving his QOL
In an attempt at treating all of the patient's symptoms, research into the use of
complementary and alternative medicine (CAM) has been conducted to determine the utility of
these treatments in addressing the unmet needs of many patients with cancer. There is
preliminary evidence that acupuncture in particular, is successful at improving many cancer
and treatment associated symptoms.
Given the potential to improve symptom control and QOL, it is thought that acupuncture
should be investigated to assess its effectiveness and feasibility in symptomatic patients
with advanced cancer. Acupuncture should be compared against another intervention, so that
the control group would also be receiving attention to their symptoms. As supportive care
has been shown to be helpful in ameliorating symptoms in terminal care, acupuncture will be
compared against this intervention. Sham acupuncture is not considered to be a good
comparison for acupuncture as it is not well tested, and its effects are often
indistinguishable from acupuncture. Recently however, some studies have reported the use of
novel techniques that prevent acupuncture-naïve patients from distinguishing between
acupuncture treatment and placebo. These techniques have yet to be independently validated.
Objectives: 1. To determine feasibility of recruiting patients and running a randomized
study that involves acupuncture at the BCCA-VIC. 2. To gather enough data to support a grant
application to fund a larger study to look at the effectiveness of acupuncture as adjunctive
treatment for the management of symptoms associated with palliative cancer care.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT02909348 -
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
|